Skip to Content

Abeona Therapeutics Inc ABEO

Morningstar Rating
$3.41 −3.95 (53.67%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ABEO is trading at a 45% discount.
Price
$7.36
Fair Value
$43.60
Uncertainty
Extreme
1-Star Price
$792.65
5-Star Price
$3.52
Economic Moat
Fypm
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ABEO is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$7.36
Day Range
$3.344.25
52-Week Range
$2.839.01
Bid/Ask
$3.41 / $3.45
Market Cap
$93.28 Mil
Volume/Avg
5.5 Mil / 471,143

Key Statistics

Price/Earnings (Normalized)
Price/Sales
20.83
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
84

Comparables

Valuation

Metric
ABEO
CBAY
VRDN
Price/Earnings (Normalized)
Price/Book Value
6.1012.653.27
Price/Sales
20.83111.012,031.07
Price/Cash Flow
Price/Earnings
ABEO
CBAY
VRDN

Financial Strength

Metric
ABEO
CBAY
VRDN
Quick Ratio
4.0710.7017.93
Current Ratio
4.1510.9618.26
Interest Coverage
−133.70−5.27−137.76
Quick Ratio
ABEO
CBAY
VRDN

Profitability

Metric
ABEO
CBAY
VRDN
Return on Assets (Normalized)
−64.39%−30.06%−42.76%
Return on Equity (Normalized)
−211.48%−51.97%−82.42%
Return on Invested Capital (Normalized)
−163.63%−30.87%−50.70%
Return on Assets
ABEO
CBAY
VRDN
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRWyjbjlpcpcLfrr$557.8 Bil
VRTX
Vertex Pharmaceuticals IncYwhzvxbqZsrmjt$103.3 Bil
REGN
Regeneron Pharmaceuticals IncZxjsgrstMtyrfy$98.8 Bil
MRNA
Moderna IncMmngyqtsDlpws$38.8 Bil
ARGX
argenx SE ADRJdxgkfvrPvxpf$21.3 Bil
BNTX
BioNTech SE ADRScvnhwcnmZrkr$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncPmhxxxnkxYhybn$18.4 Bil
BMRN
Biomarin Pharmaceutical IncHlrzyqtkFbdzjp$17.5 Bil
RPRX
Royalty Pharma PLC Class ACdjwnypdhyRysxvn$12.4 Bil
INCY
Incyte CorpDjdvtljzkWlgxwkj$11.9 Bil

Sponsor Center